Chemistry Wealth Management’s iShares US Technology ETF IYW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$221K Buy
+875
New +$201K 0.04% 200
2025
Q4
Sell
-1,540
Closed -$302K 204
2025
Q3
$302K Hold
1,540
0.06% 159
2025
Q2
$267K Buy
1,540
+30
+2% +$4.55K 0.06% 161
2025
Q1
$212K Sell
1,510
-104
-6% -$16.2K 0.05% 176
2024
Q4
$257K Sell
1,614
-270
-14% -$42.7K 0.06% 151
2024
Q3
$286K Hold
1,884
0.07% 140
2024
Q2
$284K Hold
1,884
0.07% 135
2024
Q1
$254K Sell
1,884
-84
-4% -$10.9K 0.07% 142
2023
Q4
$242K Sell
1,968
-353
-15% -$40K 0.07% 136
2023
Q3
$244K Hold
2,321
0.08% 133
2023
Q2
$253K Hold
2,321
0.08% 130
2023
Q1
$215K Buy
+2,321
New +$195K 0.07% 134

Other funds holding IYW

Chemistry Wealth Management's IYW Position: Q2 2026 in Review

Chemistry Wealth Management opened a new position in iShares US Technology ETF (IYW) in Q2 2026: 875 shares worth $221K. The stake represents 0.04% of the portfolio and ranks #200 among its holdings. This is a return to the name: Chemistry Wealth Management previously reported a position in IYW as recently as Q3 2025.

Chemistry Wealth Management first reported a position in IYW in Q1 2023 and has held it in 12 quarters since. The position peaked at $302K in Q3 2025. 403 funds tracked by Wall St. Rank hold IYW as of Q2 2026.

  • Chemistry Wealth Management held 875 shares of iShares US Technology ETF worth $221K as of Q2 2026.
  • iShares US Technology ETF was a new Chemistry Wealth Management position in Q2 2026.
  • iShares US Technology ETF made up 0.04% of Chemistry Wealth Management's portfolio in Q2 2026, its #200 holding.
  • Chemistry Wealth Management first reported a position in iShares US Technology ETF in Q1 2023 and has held it in 12 quarters since.
  • Chemistry Wealth Management's iShares US Technology ETF position peaked at $302K in Q3 2025.
  • 403 funds tracked by Wall St. Rank held iShares US Technology ETF as of Q2 2026.

Based on Chemistry Wealth Management's 13F filing for Q2 2026, filed 9 Jul 2026.